{
  "id": "5a7244aa2dc08e987e00000f",
  "type": "list",
  "question": "Which two interleukins are inhibited by Ustekinumab?",
  "ideal_answer": "Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin-12 and interleukin-23, is approved in the USA and Europe for moderate to severe plaque psoriasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28122069",
    "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
    "http://www.ncbi.nlm.nih.gov/pubmed/18703004",
    "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
    "http://www.ncbi.nlm.nih.gov/pubmed/27826996",
    "http://www.ncbi.nlm.nih.gov/pubmed/20071701",
    "http://www.ncbi.nlm.nih.gov/pubmed/28140549",
    "http://www.ncbi.nlm.nih.gov/pubmed/19934030",
    "http://www.ncbi.nlm.nih.gov/pubmed/23349185",
    "http://www.ncbi.nlm.nih.gov/pubmed/20430307",
    "http://www.ncbi.nlm.nih.gov/pubmed/23745965",
    "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
    "http://www.ncbi.nlm.nih.gov/pubmed/27450626",
    "http://www.ncbi.nlm.nih.gov/pubmed/22758911",
    "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
    "http://www.ncbi.nlm.nih.gov/pubmed/28224166",
    "http://www.ncbi.nlm.nih.gov/pubmed/20540088",
    "http://www.ncbi.nlm.nih.gov/pubmed/28423301",
    "http://www.ncbi.nlm.nih.gov/pubmed/18706417",
    "http://www.ncbi.nlm.nih.gov/pubmed/28150333",
    "http://www.ncbi.nlm.nih.gov/pubmed/24410536",
    "http://www.ncbi.nlm.nih.gov/pubmed/23278559",
    "http://www.ncbi.nlm.nih.gov/pubmed/19886505",
    "http://www.ncbi.nlm.nih.gov/pubmed/29042094",
    "http://www.ncbi.nlm.nih.gov/pubmed/28099816",
    "http://www.ncbi.nlm.nih.gov/pubmed/28300862",
    "http://www.ncbi.nlm.nih.gov/pubmed/19882785",
    "http://www.ncbi.nlm.nih.gov/pubmed/20645530",
    "http://www.ncbi.nlm.nih.gov/pubmed/24734995",
    "http://www.ncbi.nlm.nih.gov/pubmed/28087506",
    "http://www.ncbi.nlm.nih.gov/pubmed/24553909",
    "http://www.ncbi.nlm.nih.gov/pubmed/20421912",
    "http://www.ncbi.nlm.nih.gov/pubmed/18486739",
    "http://www.ncbi.nlm.nih.gov/pubmed/19344192"
  ],
  "snippets": [
    {
      "text": "The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28087506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27826996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Based on the rationale of the involvement of the IL-23/Th17 axis in AS, novel biological agents have been developed and include secukinumab, an anti-IL-17A agent and ustekinumab, an anti-IL-23 antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Besides systemic corticosteroids and cyclosporine A (CsA), options also include intravenous immunoglobulins (IVIG) and biologics such as the TNF\u03b1 inhibitors infliximab, adalimumab, and etanercept; the interleukin (IL) 12/23 antibody ustekinumab; the IL-1 receptor antagonist anakinra; and the IL-1\u03b2 antibody canakinumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28140549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objective: To determine whether blockade of the interleukin 23-helper T cell 17 (IL-23-TH17) pathway with ustekinumab represents an efficacious and, based on its proinflammatory cytokine profile, targeted treatment option in PRP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28122069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28300862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, is approved in the USA and Europe for moderate to severe plaque psoriasis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28150333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (LAE) in psoriasis patients on long-term treatment (n\u2009=\u2009199) with tumour necrosis factor (TNF)-\u03b1-antagonists (adalimumab, etanercept), and the interleukin (IL)12/23-antagonist ustekinumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28224166",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is part of interleukins IL-12 and IL-23.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The biologic, Ustekinumab (Stelara\u00ae, Centocor, Inc., Malvern, PA, USA), is a fully human monoclonal antibody with a high affinity for the shared p40 subunit of interleukins 12 and 23 (IL-12 and IL-23).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23745965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a human monoclonal antibody directed against the shared p40 subunit of interleukins 12 and 23.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27450626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction with their surface IL-12R\u03b21 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "); (2) Ustekinumab is an inhibitor of interleukins 12 and 23, which are believed to be implicated in the onset of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab (Stelara) is a therapeutic monoclonal antibody (mAb) targeted against the p40 shared subunit of IL-12 and IL-23.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the past years, the IL-23/Th17 axis has emerged as an important mechanism in the pathogenesis of PsA. Ustekinumab, a fully human IgG1\u03ba monoclonal antibody that targets the common subunit p40 of IL-12 and IL-23, has been shown in clinical trials, to be well-tolerated and effective in patients with active PsA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human interleukin-12 and interleukin-23, has demonstrated efficacy in patients with psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934030",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20430307",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706417",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12/23.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706417",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ABT-874 (Abbott Laboratories, Saint-Laurent, QC,) and ustekinumab (CNTO 1275, Ortho Biotech, Toronto, ON) are two monoclonal antibodies against interleukins 12 and 23 (IL-12/23), key mediators of T-cell differentiation in the pathogenesis of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19886505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a fully human immunoglobulin G1\u03ba monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23278559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a fully human monoclonal antibody directed against the p40 subunit shared by interleukin 12 and interleukin 23, two naturally occurring protein regulators that play an important role in immune-mediated inflammatory diseases, including psoriatic arthritis (PsA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24410536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Ustekinumab, a fully human immunoglobulin (Ig) G1K monoclonal antibody directed against the p40 subunit of interleukin (IL)-12/23, has demonstrated efficacy in patients with moderate-to-severe psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20645530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction with their surface IL-12R\u03b21 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a monoclonal antibody belonging to a newly developed class of biological, anti-cytokine medications that notably targets the p40 subunit of both IL-12 and -23, both naturally occurring proteins that are important in regulating the immune system and are understood to play a role in immune-mediated inflammatory disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20421912",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor \u03b21 subunit of the IL-12 and IL-23 receptor complexes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Ustekinumab is a human monoclonal antibody directed against the shared p40 subunit of interleukins 12 and 23.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27450626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Ustekinumab is a human monoclonal antibody that binds to the p40 subunit of interleukin (IL) 12 and IL-23 and inhibits their pharmacological activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20540088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ustekinumab is a fully human monoclonal antibody that binds with high specificity and affinity to the cytokines interleukin (IL)-12 and IL-23, thereby suppressing IL-12- and IL-23-mediated inflammation associated with psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two human anti-p40 monoclonal antibodies targeting both IL-12 and IL-23 via their shared p40 subunit have been developed: briakinumab and ustekinumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22758911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "evaluate ustekinumab an anti interleukin il 12 and il 23 antibody effects on radiographic progression in psoriatic arthritis psa we conducted preplanned integrated analyses of combined radiographic data from psummit 1 and psummit 2 phase 3 randomised controlled trials patients had active psa despite prior conventional and or biologic disease modifying antirheumatic drugs 5 66 swollen 5 68 tender joints c reactive protein 3 0 mg l documented plaque psoriasis patients psummit 1 n 615 psummit 2 n 312 were randomised to ustekinumab 45 mg 90 mg or placebo at weeks wk 0 4 and every q 12 wks at wk 16 patients with 5 improvement in tender swollen joint counts entered blinded early escape all other placebo patients received ustekinumab 45 mg at wk 24 and wk 28 then q 12 wks radiographs of hands feet at wks 0 24 52 were assessed using psa modified van der heijde sharp vdh s scores combined psummit 1 and psummit 2 changes in total vdh s scores from wk 0 to wk 24 comprised the prespecified primary radiographic analysis treatment effects were assessed using analysis of variance on van der waerden normal scores factors treatment baseline methotrexate usage and study integrated data analysis results indicated that ustekinumab treated patients regardless of dose demonstrated significantly less radiographic progression at wk 24 than did placebo recipients wk 0 24 total vdh s score mean changes 0 4 combined individual ustekinumab dose groups 1 0 placebo all p 0 02 from wk 24 to wk 52 inhibition of radiographic progression was maintained for ustekinumab treated patients and progression was substantially reduced among initial placebo recipients who started ustekinumab at wk 16 or wk 24 wk 24 wk 52 total vdh s score mean change 0 08 ustekinumab 45 and 90 mg treatments significantly inhibited radiographic progression of joint damage in patients with active psa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "discovery and mechanism of ustekinumab a human monoclonal antibody targeting interleukin 12 and interleukin 23 for treatment of immune mediated disorders",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "a randomized trial of ustekinumab a human interleukin 12 23 monoclonal antibody in patients with moderate to severe crohn s disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706417",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "human leucocyte antigen cw6 as a predictor for clinical response to ustekinumab an interleukin 12 23 blocker in chinese patients with psoriasis a retrospective analysis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24734995",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ustekinumab a human immunoglobulin g1 kappa igg1k monoclonal antibody that binds with high affinity to human interleukin 12 and interleukin 23 has demonstrated efficacy in patients with psoriasis the objective of this study was to perform exposure response modeling to increase the understanding of reduction in disease severity following treatment with ustekinumab in patients with moderate to severe psoriasis who participate in two phase iii studies phoenix 1 and phoenix 2 patients were randomly assigned to receive ustekinumab 45 mg or 90 mg n 1312 11 624 psoriasis area and severity index pasi scores or placebo n 665 3278 pasi scores disease severity was assessed using pasi scores a population mechanism based exposure response model of ustekinumab using nonmem was developed using serum ustekinumab concentrations and pasi scores the pharmacodynamic response effect was the reduction in pasi score the placebo effect although minor was also integrated into the model none of the covariate factors evaluated eg demographics baseline disease characteristics comorbidities significantly contributed to the between subject variability in the pharmacodynamic parameters the developed exposure response model can serve as a basis to support future alternative dosing regimens for ustekinumab in patients with moderate to severe plaque psoriasis a robust exposure response relationship has been confirmed for ustekinumab in psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "interleukin 23 is thought to be critical to the pathogenesis of psoriasis we compared risankizumab bi 655066 a humanized igg1 monoclonal antibody that inhibits interleukin 23 by specifically targeting the p19 subunit and thus prevents interleukin 23 signaling and ustekinumab an interleukin 12 and interleukin 23 inhibitor in patients with moderate to severe plaque psoriasis we randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab a single 18 mg dose at week 0 or 90 mg or 180 mg doses at weeks 0 4 and 16 or ustekinumab 45 or 90 mg according to body weight at weeks 0 4 and 16 the primary end point was a 90 or greater reduction from baseline in the psoriasis area and severity index pasi score at week 12 at week 12 the percentage of patients with a 90 or greater reduction in the pasi score was 77 64 of 83 patients for risankizumab 90 mg and 180 mg groups pooled as compared with 40 16 of 40 patients for ustekinumab p 0 001 the percentage of patients with a 100 reduction in the pasi score was 45 in the pooled 90 mg and 180 mg risankizumab groups as compared with 18 in the ustekinumab group efficacy was generally maintained up to 20 weeks after the final dose of 90 or 180 mg of risankizumab in the 18 mg and 90 mg risankizumab groups and the ustekinumab group 5 patients 12 6 patients 15 and 3 patients 8 respectively had serious adverse events including two basal cell carcinomas and one major cardiovascular adverse event there were no serious adverse events in the 180 mg risankizumab group in this phase 2 trial selective blockade of interleukin 23 with risankizumab was associated with clinical responses superior to those associated with ustekinumab this trial was not large enough or of long enough duration to draw conclusions about safety funded by boehringer ingelheim clinicaltrials gov number nct02054481.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28423301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1 for adults with plaque psoriasis after failure of topical symptomatic treatments and puva therapy several systemic immunosuppressive agents are acceptable for severe disease methotrexate then ciclosporin and possible a tnf alpha antagonist etanercept etc 2 ustekinumab is an inhibitor of interleukins 12 and 23 which are believed to be implicated in the onset of psoriasis it is authorized in the european union for patients who fail to respond to conventional systemic treatments 3 in one trial with a low level of evidence single blind 2 subcutaneous injections of ustekinumab at an interval of 4 weeks appeared to be statistically more effective than twice weekly subcutaneous injections of etanercept for 12 weeks more patients achieved a 75 reduction in the score most widely used to evaluate the extent and intensity of plaque psoriasis lesions pasi score about 71 versus 57 the results beyond this period have not been reported 4 two randomised double blind placebo controlled trials in a total of 1996 patients showed that at least two thirds of patients treated with ustekinumab achieved at least a 75 reduction in their pasi score versus fewer than 4 with placebo 5 in animal studies interleukin 12 and 23 inhibitors cause cancer there is therefore a high risk of cancer developing during prolonged treatment with ustekinumab 6 the main adverse effects identified in clinical trials include infections injection site reactions psychological disorders and development of anti ustekinumab antibodies 7 there is insufficient follow up to evaluate the cardiac risks associated with ustekinumab 8 as maintenance therapy ustekinumab is administered as one subcutaneous injection every 12 weeks this practical advantage compared to tnf alpha antagonists must be weighed against the risks inherent in prolonged immunosuppression 9 in summary for symptomatic relief of patients whose psoriasis poses major problems despite treatment with methotrexate or ciclosporin in the absence of a better alternative it is better to use a tnf alpha antagonist and to avoid exposing patients to the risks associated with ustekinumab particularly its carcinogenic risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "biologic agents offer a range of new therapeutic options for patients with psoriasis however the relative benefit risk profiles of such therapies are not well known we compared two biologic agents ustekinumab an interleukin 12 and interleukin 23 blocker and etanercept an inhibitor of tumor necrosis factor alpha for the treatment of psoriasis we randomly assigned 903 patients with moderate to severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekinumab at weeks 0 and 4 or high dose etanercept 50 mg twice weekly for 12 weeks the primary end point was the proportion of patients with at least 75 improvement in the psoriasis area and severity index pasi at week 12 a secondary end point was the proportion with cleared or minimal disease on the basis of the physician s global assessment assessors were unaware of the treatment assignments the efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12 there was at least 75 improvement in the pasi at week 12 in 67 5 of patients who received 45 mg of ustekinumab and 73 8 of patients who received 90 mg as compared with 56 8 of those who received etanercept p 0 01 and p 0 001 respectively similarly 65 1 of patients who received 45 mg of ustekinumab and 70 6 of patients who received 90 mg of ustekinumab had cleared or minimal disease according to the physician s global assessment as compared with 49 0 of those who received etanercept p 0 001 for both comparisons among patients who did not have a response to etanercept 48 9 had at least 75 improvement in the pasi within 12 weeks after crossover to ustekinumab one or more adverse events occurred through week 12 in 66 0 of patients who received 45 mg of ustekinumab and 69 2 of patients who received 90 mg of ustekinumab and in 70 0 who received etanercept 1 9 1 2 and 1 2 respectively had serious adverse events safety patterns were similar before and after crossover from etanercept to ustekinumab the efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high dose etanercept over a 12 week period in patients with psoriasis clinicaltrials gov number nct00454584.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "repeated subcutaneous injections of a monoclonal antibody against the p40 subunit of interleukins 12 and 23 ustekinumab were used to treat patients with relapsing remitting multiple sclerosis rrms to assess the drug s safety efficacy and pharmacokinetics in this phase ii multicentre randomised double blind placebo controlled study 249 patients with rrms aged 18 65 years were eligible to be assigned equally by a central randomisation procedure based on study site and presence or absence of gadolinium enhancing t1 weighted lesions at baseline to one of five groups that received placebo or four different ustekinumab dosages at weeks 0 1 2 3 7 11 15 and 19 ustekinumab doses were 27 mg 90 mg q8w 90 mg or 180 mg the 90 mg q8w dosage group received placebo substitute at weeks 7 and 15 the primary endpoint was the cumulative number of new gadolinium enhancing t1 weighted lesions on serial cranial mri through week 23 patients were followed up through week 37 analysis was by intention to treat this trial is registered with clinicaltrials gov number nct00207727 from august 2004 to december 2006 249 patients underwent randomisation 49 for placebo 50 for each ustekinumab group ustekinumab treatment did not show a significant reduction in the primary endpoint for any dosage groups versus placebo at week 37 adverse events occurred in 38 78 placebo treated patients and 170 85 ustekinumab treated patients with infections most commonly reported serious adverse events occurred in one 2 placebo treated patient and six 3 ustekinumab treated patients malignant diseases were reported in two patients shortly after the initiation of ustekinumab treatment both patients were withdrawn from the trial and given appropriate treatment which resulted in complete remission no serious infections cardiovascular events or exacerbation of demyelinating events occurred a dose dependent increase in serum concentrations of ustekinumab was recorded ustekinumab is generally well tolerated but does not show efficacy in reducing the cumulative number of gadolinium enhancing t1 weighted lesions in multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18703004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "interleukin 12 and interleukin 23 are inflammatory cytokines implicated in crohn s disease pathophysiology ustekinumab is a monoclonal antibody against the p40 subunit of interleukin 12 23 we performed a double blind cross over trial of the clinical effects of ustekinumab in 104 patients with moderate to severe crohn s disease population 1 patients were given subcutaneous placebo at weeks 0 3 then ustekinumab at weeks 8 11 subcutaneous ustekinumab at weeks 0 3 then placebo at weeks 8 11 intravenous placebo at week 0 then ustekinumab at week 8 or intravenous ustekinumab at week 0 then placebo at week 8 furthermore an open label trial evaluated the effects of 4 weekly subcutaneous injections or 1 intravenous infusion of ustekinumab in 27 patients who were primary or secondary nonresponders to infliximab population 2 in population 1 clinical response rates for the combined groups given ustekinumab and placebo were 53 and 30 p 02 respectively at weeks 4 and 6 and 49 and 40 p 34 respectively at week 8 in a subgroup of 49 patients who were previously given infliximab neither primary nor secondary nonresponders clinical response to ustekinumab was significantly greater than the group given placebo p 05 through week 8 in population 2 the clinical responses at week 8 to subcutaneous and intravenous ustekinumab were 43 and 54 respectively there was no increase in the number of adverse or serious adverse events in patients given ustekinumab through week 8 compared with placebo ustekinumab induced a clinical response in patients with moderate to severe crohn s disease especially in patients previously given infliximab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706417",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "anti p40 antibodies ustekinumab and briakinumab blockade of interleukin 12 and interleukin 23 in the treatment of psoriasis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20430307",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "efficacy and safety of ustekinumab a human interleukin 12 23 monoclonal antibody in patients with psoriasis 76 week results from a randomised double blind placebo controlled trial phoenix 1",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18486739",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ustekinumab is a fully human monoclonal antibody directed against the p40 subunit shared by interleukin 12 and interleukin 23 two naturally occurring protein regulators that play an important role in immune mediated inflammatory diseases including psoriatic arthritis psa in september of 2009 the us fda approved ustekinumab for the treatment of adult patients with moderate to severe plaque psoriasis beginning in november of 2009 janssen biotech formerly centocor biotech the developer of ustekinumab initiated clinical trials to investigate the efficacy of ustekinumab in the treatment of other inflammatory disorders including psa phase ii and phase iii studies showed both a good safety profile and significant efficacy for ustekinumab in the treatment of psa leading to the drug s approval in both europe and the usa in an immunotherapy market currently dominated by anti tnf \u03b1 drugs for the treatment of psa ustekinumab offers an alternative option for patients with psa including those unresponsive to methotrexate and the tnf \u03b1 inhibitory agents currently approved for this potentially debilitating disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24410536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ustekinumab is a fully human monoclonal antibody that binds with high specificity and affinity to the cytokines interleukin il 12 and il 23 thereby suppressing il 12 and il 23 mediated inflammation associated with psoriasis in two large phase iii trials in patients with moderate to severe plaque psoriasis significantly more subcutaneous ustekinumab 45 or 90 mg recipients administered as two injections 4 weeks apart than placebo recipients achieved a 75 improvement on the psoriasis area and severity index pasi 75 score at 12 weeks other efficacy measures including the physician s global assessment of clinical response at week 12 also favored ustekinumab over placebo psoriatic symptom control was maintained during ustekinumab maintenance therapy administered once every 12 weeks for up to 76 weeks in a phase ii trial in patients with active plaque psoriasis and psoriatic arthritis signs and symptoms of arthritis and psoriatic symptom control were improved to a greater extent with ustekinumab than with placebo at 12 weeks based on the proportion of patients achieving a 20 improvement in american college of rheumatology response criteria arthritis or pasi 75 skin symptoms health related quality of life assessed using the dermatology life quality index and the health assessment questionnaire disability index was improved to a significantly greater extent with ustekinumab than with placebo at week 12 subcutaneous ustekinumab was generally well tolerated in clinical trials with most treatment emergent adverse events being of mild severity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the choice of therapeutic agents for patients with moderate to severe psoriasis has expanded significantly in the past decade with new understanding of the immunologic basis of psoriasis multiple new potential targets for therapy have been identified it is likely that a series of new medications to focus on the newly identified pathways is on the horizon the first pathway targeted by new medications focuses on the p40 subunit that is shared by interleukin il 12 and il 23 two human anti p40 antibodies have been used therapeutically in psoriasis to date ustekinumab cnto 1275 stelara centocor horsham pa and briakinumab abt 874 abbott abbott park il ustekinumab was recently approved by the united states food and drug administration making it the first medication approved in the united states to work by this pathway while briakinumab is currently in phase iii clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20430307",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "interleukin-12, interleukin-23"
}